Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899204 · ClinicalTrials.gov registry record
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
A clinical trial of Atopic Dermatitis and Dermatitis, Atopic, sponsored by Pfizer.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT06899204 is a study of Atopic Dermatitis and Dermatitis, Atopic that is actively recruiting participants, run by Pfizer. The registered enrollment target is 150 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06899204, a study of Atopic Dermatitis and Dermatitis, Atopic, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States. The aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.
Conditions Studied
Interventions
- DRUG Abrocitinib
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2026-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06899204
The ClinicalTrials.gov registry entry for NCT06899204 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (75% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Abrocitinib is the first listed.
NCT06899204 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06899204 about?
NCT06899204 is a clinical study titled "Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.". This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the ...
What is the current status of trial NCT06899204?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2026-01-13. Estimated completion is 2026-09-30.
What conditions does trial NCT06899204 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Dermatitis, Atopic, Atopic Dermatitis, Unspecified.
What interventions are being tested in trial NCT06899204?
The interventions under investigation include: Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT06899204?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899204 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.